Difference between revisions of "Messenger RNA Vaccine"
| Line 43: | Line 43: | ||
=Roadmap Model using OPM= | =Roadmap Model using OPM= | ||
==Discovery== | ===Discovery=== | ||
The discovery process spans from obtaining the genetic information of the target virus to the phase just before the commencement of human clinical trials. | The discovery process spans from obtaining the genetic information of the target virus to the phase just before the commencement of human clinical trials. | ||
[[File:2MRV_03_01.png|frameless|3000px|OPM1]] | [[File:2MRV_03_01.png|frameless|3000px|OPM1]] | ||
==Development== | ===Development=== | ||
The development process begins with the first human clinical trial and continues until the drug receives approval. | The development process begins with the first human clinical trial and continues until the drug receives approval. | ||
[[File:2MRV_03_02.png|frameless|3000px|OPM2]] | [[File:2MRV_03_02.png|frameless|3000px|OPM2]] | ||
==Manufacturing process== | ===Manufacturing process=== | ||
The manufacturing process begins after the drug has been approved. It starts with the assembly of each ingredient component and continues through to the shipment of the finished vaccine products. | The manufacturing process begins after the drug has been approved. It starts with the assembly of each ingredient component and continues through to the shipment of the finished vaccine products. | ||
[[File:2MRV_03_03.png|frameless|3000px|OPM3]] | [[File:2MRV_03_03.png|frameless|3000px|OPM3]] | ||
==Actual Vaccination Situation== | ===Actual Vaccination Situation=== | ||
The Actual Vaccination Situation refers to the process that starts with receiving the vaccine products at the vaccination site and culminates in individuals gaining immunity after being administered the vaccines. | The Actual Vaccination Situation refers to the process that starts with receiving the vaccine products at the vaccination site and culminates in individuals gaining immunity after being administered the vaccines. | ||
Revision as of 23:44, 11 October 2023
Roadmap Overview
Roadmap Overview of mRNA Vaccine Technology
Discovery (DCY)
- The initial phase focuses on identifying and understanding the genetic composition of the target virus and creating a blueprint for the mRNA vaccine.
- SVI: Structural inference from viral nucleotide information
- MRD: mRNA design
- MRS: mRNA Synthesis
- MRM: mRNA modification
- LMS: Lipid Membrane Synthesis
Development (DVT)
- This stage involves testing the designed vaccine in human trials and ensuring its safety and efficacy.
- RMH: Risk Management of the Human Body
- CTM: Clinical Trial Management
Manufacturing Process (MFP)
- Once approved, the vaccine goes into mass production, ensuring that each component is assembled accurately and in the required quantities.
- MMS: mRNA mass synthesis (scale-up)
- MLS: Massive lipid synthesis
- MSB: Mass synthesis of buffers and other excipients
- MVA: Mass vaccine assembly
Actual Vaccination Situation
- This final stage involves the distribution and administration of the vaccine to individuals, ensuring that they gain immunity.
(Note: No specific sub-processes are provided for this step)
Vaccine Development Technologies (1VDT)
- LAV: Live-attenuated vaccines
- IAV: Inactivated vaccines
- SUV: Subunit vaccines
- TXV: Toxoid vaccines
- VVV: Viral vector vaccines
- MRV: Messenger RNA (mRNA) vaccine
Note: This roadmap gives a structured overview of the mRNA vaccine technology, breaking down each phase into specific processes and tasks. Each step is crucial to ensuring the safety, efficacy, and availability of the vaccine to the masses.
Design Structure Matrix (DSM) Allocation
The DSM illustrates the interplay between the tools and methods that constitute the Messenger RNA Vaccine. A 'X' sign denotes that the techniques are interconnected.
Roadmap Model using OPM
Discovery
The discovery process spans from obtaining the genetic information of the target virus to the phase just before the commencement of human clinical trials.
Development
The development process begins with the first human clinical trial and continues until the drug receives approval.
Manufacturing process
The manufacturing process begins after the drug has been approved. It starts with the assembly of each ingredient component and continues through to the shipment of the finished vaccine products.
Actual Vaccination Situation
The Actual Vaccination Situation refers to the process that starts with receiving the vaccine products at the vaccination site and culminates in individuals gaining immunity after being administered the vaccines.
Figures of Merit
XXX
Alignment with Company Strategic Drivers
XXX
Positioning of Company vs. Competition
XXX
Technical Model
XXX
Financial Model
XXX